Galmed Pharmaceuticals Ltd

GLMD60

Penny Stock

$3.04arrow_drop_up1.33%$0.04

Penny Stock

GLMD60

$3.04

arrow_drop_up1.33%$0.04

Penny Stock

Performance History

Key Stats
Open	$2.86
Prev. Close	$2.94
EPS	-10.44
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$4.52M
PE Ratio	-

	LOW	HIGH
Day Range	2.76	3.06
52 Week Range	2.73	23.80

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-10.44

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Galmed Pharmaceuticals Ltd (GLMD)

Galmed Pharmaceuticals Ltd (GLMD) is a pharmaceutical company that specializes in the development and commercialization of oral therapy for the treatment of liver diseases. The company's main focus is on the development of Aramchol, a fatty acid bile acid (FABAC) agonist that has the potential to treat non-alcoholic steatohepatitis (NASH), a chronic liver disease. GLMD's stock price history has shown both volatility and upward momentum over the years, reflecting the market's anticipation of the potential of Aramchol.

The company's stock, traded under the ticker symbol GLMD, has seen significant fluctuations in its price over the years. GLMD's quote as of the latest data shows a stock price of (insert current stock price). Despite the volatility, Galmed Pharmaceuticals has been able to attract investor interest due to its focus on developing innovative treatments for liver diseases. The stock has witnessed both sharp increases and declines in response to various news and events related to the company's pipeline and clinical trials.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Allen Baharaff
Headquarters: Tel Aviv
Employees: 4
Exchange: NASDAQ

add Galmed Pharmaceuticals Ltd to watchlist

Keep an eye on Galmed Pharmaceuticals Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Galmed Pharmaceuticals Ltd's (GLMD) price per share?

The current price per share for Galmed Pharmaceuticals Ltd (GLMD) is $3.04. The stock has seen a price change of $0.04 recently, indicating a 1.33% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Galmed Pharmaceuticals Ltd (GLMD)?

For Galmed Pharmaceuticals Ltd (GLMD), the 52-week high is $23.8, which is 682.89% from the current price. The 52-week low is $2.73, the current price is 11.36% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Galmed Pharmaceuticals Ltd (GLMD) a growth stock?

Galmed Pharmaceuticals Ltd (GLMD) has shown an average price growth of -6.8% over the past three years. It has received a score of 94 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Galmed Pharmaceuticals Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Galmed Pharmaceuticals Ltd (GLMD) stock price performance year to date (YTD)?

As of the latest data, Galmed Pharmaceuticals Ltd (GLMD) has a year-to-date price change of -42.38%. Over the past month, the stock has experienced a price change of -35.04%. Over the last three months, the change has been -15.84%. Over the past six months, the figure is -36.28%. Looking at a longer horizon, the five-year price change stands at -99.63%.

help

Is Galmed Pharmaceuticals Ltd (GLMD) a profitable company?

Galmed Pharmaceuticals Ltd (GLMD) has a net income of -$6.91M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at $7.49M. Furthermore, the EBITDA is -$6.14M.

help

What is the market capitalization of Galmed Pharmaceuticals Ltd (GLMD)?

Galmed Pharmaceuticals Ltd (GLMD) has a market capitalization of $4.52M. The average daily trading volume is 3.04, indicating the stock's liquidity and investor engagement.